MiNK Therapeutics, Inc. (INKT) Key Statistics & Financial Ratios

MiNK Therapeutics, Inc. (INKT) — Price $11.59 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for MiNK Therapeutics, Inc. (INKT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction.

Stock Data

Price$11.59
Market Cap$58M
Enterprise Value$48.9M
Beta0.35
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-4.77
Price / Book-4.09
P/S0.00
EV/EBITDA-4.34
EV/Sales0.00
EV/FCF-0.02
P/FCF-0.03
Earnings Yield-19.51%
FCF Yield-3615.43%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity83.45%
Return on Assets-118.15%
Return on Invested Capital-604.20%
Return on Capital Employed-604.20%

Financial Health

Current Ratio1.23
Quick Ratio1.23
Cash Ratio1.16
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA0.78
Interest Coverage0.00

Per-Share Data

Revenue per share0.00
Book Value per share-2.79
Cash per share1.75
FCF per share-415.56
Tangible Book Value per share-2.79
Dividend per share0.00

Related companies: CRVO · EQ · GANX · HOWL · IOBT · NRXP · OSTX

Explore sector: Healthcare · Biotechnology

More sections of INKT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks